| Literature DB >> 34205461 |
Eyal Ben-Arie1, Tzu-Hsuan Wei2, Hung-Chi Chen3, Tsung-Chun Huang3, Wen-Chao Ho4, Chiu-Ming Chang2, Pei-Yu Kao5,6, Yu-Chen Lee1,2,7.
Abstract
Malnourishment is prevalent in patients suffering from head and neck cancer. The postoperative period is crucial in terms of nutritional support, especially after composite resection and reconstruction surgery. These patients present with a number of risk factors that aggravate feeding intolerance, including postoperative status, prolonged immobility, decreased head elevation, mechanical ventilation, and applied sedative agents. Routine management protocols for feeding intolerance include prokinetic drug use and post-pyloric tube insertion, which could be both limited and accompanied by detrimental adverse events. This single-blind clinical trial aimed to investigate the effects of acupuncture in postoperative feeding intolerance in critically ill oral and hypopharyngeal cancer patients. Twenty-eight patients were randomized into two groups: Intervention group and Control group. Interventions were administered daily over three consecutive postoperative days. The primary outcome revealed that the intervention group reached 70% and 80% of target energy expenditure (EE) significantly earlier than the control group (4.00 ± 1.22 versus 6.69 ± 3.50 days, p = 0.012), accompanied by higher total calorie intake within the first postoperative week (10263.62 ± 1086.11 kcals versus 8384.69 ± 2120.05 kcals, p = 0.004). Furthermore, the intervention group also needed less of the prokinetic drug (Metoclopramide, 20.77 ± 48.73 mg versus 68.46 ± 66.56 mg, p = 0.010). In conclusion, digestion-specific acupuncture facilitated reduced postoperative feeding intolerance in oral and hypopharyngeal cancer patients.Entities:
Keywords: ICU; acupuncture; critically ill; digestion; energy expenditure (EE); feeding intolerance; hypopharyngeal cancer; oral cancer; postoperative
Year: 2021 PMID: 34205461 PMCID: PMC8234819 DOI: 10.3390/nu13062110
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Recruitment and participant flow chart depicting information regarding enrolment, interventions, and analytic processes. Post randomization, one patient was excluded from each group and not analyzed.
Baseline characteristics.
| Intervention Group | Control Group | |||
|---|---|---|---|---|
| Age | 52.77 ± 6.50 | 55.62 ± 9.87 | 0.479 | |
| Gender (M) | 13 (100%) | 13 (100%) | 1.00 | |
| Weight | 63.39 ± 12.99 | 68.95 ± 15.52 | 0.579 | |
| Height | 167.44 ± 5.36 | 170.50 ± 5.32 | 0.081 | |
| BMI | 22.54 ± 4.34 | 23.62 ± 4.69 | 0.687 | |
| No. of patients with BMI | ||||
| <18.5 | 3(23%) | 1(7.7%) | 0.511 | |
| 18.5–20.5 | 1(7.7%) | 3(23%) | 0.511 | |
| >20.5 | 9(69.2%) | 9(69.2%) | 1.000 | |
| Target EE (kcal) | Predictive equation | 2031.23 ± 146.93 | 2029.62 ± 195.52 | 0.880 |
| Simplistic weight-based equation | 1584.81 ± 324.64 | 1723.85 ± 387.89 | 0.579 | |
| BEE (kcal) | 1418.23 ± 217.86 | 1490.85 ± 279.97 | 0.687 | |
| Nutrition risk screening 2002: | Low risk | 0 (0%) | 0 (0%) | 1.00 |
| Medium risk | 3 (23.1%) | 0 (0%) | 0.336 | |
| High risk | 10 (76.9%) | 13(100%) | 0.336 | |
| Cancer stage: | Stage I | 2 (15.4%) | 2 (15.4%) | 1.00 |
| Stage II | 3 (23.1%) | 1 (7.7%) | 0.569 | |
| Stage III | 1 (7.7%) | 4 (30.8%) | 0.252 | |
| Stage IV | 6 (46.2%) | 3 (23.1%) | 0.376 | |
| Recurrent cancer status | 1(7.7%) | 1(7.7%) | 1.00 | |
| Types of surgery: | Primary tumor resection with reconstruction | 8 (61.5%) | 11(84.6%) | 0.336 |
| Functional or cosmetic reconstruction | 5(38.5%) | 2(15.4%) | 0.336 | |
| Previous free flaps | 2.08 ± 1.80 | 1.46 ± 0.78 | 0.579 | |
| Previous cancer-related surgeries | 3.23 ± 2.98 | 1.62 ± 0.87 | 0.243 |
M = male, EE = energy expenditure, BEE = basal energy expenditure, BMI = Body Mass Index. Data presented as mean ± standard deviation, or as number of patients and percent (%).
Target EE (in kcal) and the duration required to achieve it in both groups.
| Intervention Group ( | Control Group ( | ||
|---|---|---|---|
| Target EE by predictive equation(kcal) | 2031.23 ± 146.93 | 2029.62 ± 195.52 | 0.880 |
| 70% of target EE(days) | 3.54 ± 1.05 | 5.62 ± 2.96 | 0.016 * |
| 80% of target EE | 4.00 ± 1.22 | 6.69 ± 3.50 | 0.012 * |
| 100% of target EE | 8.31 ± 4.03 | 8.62 ± 3.84 | 0.545 |
| Target EE by simplistic weight-based equation(kcal) | 1584.81 ± 324.64 | 1723.85 ± 387.89 | 0.579 |
| 70% of target EE(days) | 3.00 ± 1.08 | 4.92 ± 3.09 | 0.034 * |
| 80% of target EE | 3.38 ± 1.04 | 5.38 ± 2.99 | 0.019 * |
| 100% of target EE | 4.54 ± 3.13 | 7.15 ± 4.12 | 0.029 * |
| Total Calories intake for first week | 10263.62 ± 1086.11 | 8384.69 ± 2120.05 | 0.004 * |
EE = energy expenditure. Data are presented as mean ± standard deviation. * Refers to significant p-value levels of lower to 0.05.
Figure 2Repeat measures of EE percentages out of target EE over time. (A) This figure represents a visual description of a repeat measurements on days 4, 5 and 6 using a generalized linear model. Results are between groups p = 0.011 *, and between timelines p = 0.000 *. EE = energy expenditure. * refers to significant p-value levels lower to 0.05. (B) The observed tendency in reaching postoperative target EE over seven days. EE = energy expenditure.
Secondary outcomes revealed significantly less use of the prokinetics drug in the intervention group.
| Intervention Group | Control Group | ||
|---|---|---|---|
| Prokinetic drug use (Metoclopramide, mg) | 20.77 ± 48.73 | 68.46 ± 66.56 | 0.010 * |
| Post-pyloric tube use | 1(7.7%) | 0 | 0.762 |
| Parental nutrition use | 0 | 1(7.7%) | 0.762 |
| Diarrhea (days) | 1.46 ± 1.76 | 2.23 ± 2.17 | 0.418 |
| Fever days (>38 °C) | 2.62 ± 2.47 | 3.00 ± 2.83 | 0.545 |
| ICU days | 7.92 ± 7.52 | 8.23 ± 4.30 | 0.169 |
| Hospital days | 18.92 ± 5.38 | 22.77 ± 10.22 | 0.418 |
| MV days | 5.00 ± 3.34 | 6.54 ± 3.93 | 0.223 |
| Mortality | 0 | 0 | 1.00 |
ICU = intensive care unit, MV = mechanical ventilation. Data are presented as mean ± standard deviation. * Refers to significant p-value levels lower to 0.05.
The albumin level dropped significantly in both groups after operation.
| Intervention Group | Control Group | |||
|---|---|---|---|---|
| Albumin | Before OP | 3.75 ± 0.71( | 3.84 ± 0.86( | 0.798 |
| After OP | 3.18 ± 0.39( | 2.93 ± 0.43( | 0.186 | |
| 0.042 * | 0.036 * |
There was no difference between groups. IV Albumin = intravenous albumin, OP = operation. Data are presented as mean ± standard deviation, and number of patients (n). * Refers to significant p-value levels lower to 0.05.